- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04233476
A Study of 99mTc-3PRGD2 Injection in Lung Cancer Patient
An Evaluation of the Efficacy and Safety of Technetium [99mTc] Hydrazinonicotinamide PEGylated Bicyclic RGD Peptide Injection in a Multicenter, Open, Self-controlled Clinical Trial for the Lymph Node Metastasis in Lung Tumors
The study drug Technetium [99mTc] Hydrazinonicotinamide PEGylated Bicyclic RGD Peptide Injection(99mTc-3PRGD2) of this study is a novel radioactive diagnostic preparation for clinical use as a nuclear medicine molecular probe for tumor SPECT/CT imaging.
After 99mTc-3PRGD2 is injected into the body, it is specifically taken up by integrin receptor-positive tumor tissue, and the image of tumor tissue can be obtained by SPECT/CT, This can be used for molecular imaging diagnosis and individualized treatment of common tumors.
The primary objective of this study was to evaluate the efficacy of 99mTc-3PRGD2 for the diagnosis of lymph node metastasis in lung tumors. The minor objective was to evaluate the efficacy of 99mTc-3PRGD2 in the differential diagnosis of benign and malignant lung tumors and the safety of 99mTc-3PRGD2 in vivo of humans.
Study Overview
Detailed Description
This study strictly obeyed to the result by pathological diagnoses standard. The evaluation of the efficacy of 99mTc-3PRGD2 in the diagnosis of lymph node metastasis of lung tumors is based on a multi-center, open, self-controlled clinical trial.
This study involves 10 research sites and a total of about 400 qualified patients who met the protocol requirements in China, besides, they were previously diagnosed by 18F FDG PET / CT with positive results in pulmonary occupying and lymph nodes (hilar or mediastinum) uptake. At least 270 participants' surgical pathology report were required. After screening the patients, the intravenous injection of 99mTc-3PRGD2 with a dose of 0.3 mCi / kg was performed, followed by SPECT / CT plain scan and chest tomography scan. The doctors are responsible for patients about whether they should take lymphadenectomy and obtain the surgical pathology reports.
At the same time, the safety of 99mTc-3PRGD2 injection in human body was evaluated. This study strictly obeyed to the result by pathological diagnoses standard which uses the four-grid table to calculate the accuracy, sensitivity and specificity of 99mTc-3PRGD2 SPECT/CT diagnosis. Besides, the diagnostic results of 18F-FDG Positron Emission computed Tomography/Chest Tomography (PET/CT) were compared to evaluate the effectiveness of 99mTc-3PRGD2 SPECT/CT in the diagnosis of lymph node metastasis and differential diagnosis of benign and malignant lung tumors as well as evaluate the safety of 99mTc-3PRGD2 injection in vivo of humans.
This study invited an independent imaging evaluation committee to evaluate images obtained with 18F-FDG PET/CT, 99mTc-3PRGD2 SPECT/CT and enhanced CT.
Study duration: The start of the study is defined as the date on which the first participant signed the Informed Consent Form (ICF); the End Of the Study (EOS) was defined as the end of the collection of the final participant safety assessment data.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100032
- Peking Union Medical College Hospital
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050000
- Fourth Hospital of Hebei Medical University
-
-
Jilin
-
Changchun, Jilin, China, 130000
- Sino-Japanese Friendship Hospital of Jilin Universit
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030000
- First Hospital of Shanxi Medical Universit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Requirements for participants:
Patients only meet all the following requirements are qualified to this study
- Voluntarily participate in and sign the ICF.
- Age older than (or equal to) 18 years.
- Lung solid nodules with the longest diameter ≥ 1.5cm, shortest diameter ≥ 1.0 cm (diagnosed by CT) and scheduled for surgical resection.
- Patients after 18F-FDG PET / CT examination with the positive results in pulmonary space occupying and lymph node (hilar or mediastinal) uptake.
- Willing and able to follow the visit schedule, dosing plan, various checks.
- Clinical laboratory tests and other indicators are in the normal range or not but do not affect the relevant examination and treatment.
Patients cannot be enrolled as long as they match one of them:
Patients meet any one of the following requirements are exclusive to this study:
- Female patients who are preparing for pregnancy within 6 months or are in pregnancy or lactation
- Allergic to test drugs, allergies or allergies to multiple drugs
- The results of enhanced CT examination are non-solid component ground glassy nodules.
- Fasting blood glucose levels above 7.0 mmol/L before injection of 18F-FDG (fast glucose meter test)
- Bodyweight is more than 100 kg
- Claustrophobia patients
- Patients cannot tolerate two arms up and lie for 15~30 minutes
- The investigator believes that it is not appropriate to participate in this clinical trial.
- Those who have participated in clinical trials or are participating in other clinical trials in the past month.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 99mTc-3PRGD2
Volunteers were injected intravenously and then scanned by SPECT/CT.
Drugs use generic name:Technetium [99mTc] Hydrazinonicotinamide PEGylated Bicyclic RGD Peptide Injection dosage form:Injection dosage:0.3mCi/kg
frequency:single dose
|
Volunteers were injected intravenously and then scanned by SPECT/CT.
Drugs use generic name:Technetium [99mTc] Hydrazinonicotinamide PEGylated Bicyclic RGD Peptide Injection dosage form:Injection dosage:0.3mCi/kg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Specificity of diagnostic efficacy of 99mTc-3PRGD2 for lymph node metastasis of lung tumors
Time Frame: post-intervention at 10 months
|
The study results are strictly according to pathological diagnoses standard when evaluating whether the efficacy of 99mTc-3PRGD2 in the diagnosis of lymph node metastasis of lung tumors is superior to 18F-FDG PET/CT.
|
post-intervention at 10 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Accuracy and sensitivity of 99mTc-3PRGD2 for diagnostic efficacy of lymph node metastasis in lung cancer
Time Frame: post-intervention at 10 months
|
The study results are strictly according to pathological diagnoses standard when evaluating the accuracy and sensitivity of 99mTc 3PRGD2 SPECT/CT by comparing to the enhanced CT for the diagnosis of lymph node metastasis of lung tumors.
|
post-intervention at 10 months
|
Accuracy, sensitivity and specificity of 99mTc-3PRGD2 for diagnostic efficacy of benign and malignant lung tumors
Time Frame: post-intervention at 10 months
|
The study results are strictly according to pathological diagnoses standard when evaluating the accuracy, sensitivity and specificity of 99mTc 3PRGD2 SPECT/CT by comparing to enhanced CT for the diagnosis of lymph node metastasis of lung tumors.
|
post-intervention at 10 months
|
Accuracy, sensitivity and specificity of 99mTc-3PRGD2 for diagnostic efficacy of pulmonary lymph node metastasis
Time Frame: post-intervention at 10 months
|
The study results are strictly according to pathological diagnoses standard when evaluating the accuracy, sensitivity and specificity of 99mTc 3PRGD2 SPECT/CT by comparing to enhanced CT for the diagnosis of lymph node metastasis of lung tumors.
|
post-intervention at 10 months
|
Accuracy, sensitivity and specificity of 99mTc-3PRGD2 for diagnostic efficacy of benign and malignant lung tumors
Time Frame: post-intervention at 10 months
|
The study results are strictly according to pathological diagnoses standard when evaluating the accuracy, sensitivity and specificity of 99mTc 3PRGD2 SPECT/CT by comparing to enhanced CT for the differential diagnosis of benign and malignant lung tumors.
|
post-intervention at 10 months
|
Incidence of adverse events
Time Frame: 3 days
|
Evaluating the safety of 99mTc 3PRGD2 SPECT/CT in vivo of humans.
|
3 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Naixin Liang, professor, Peking Union Medical College Hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FSRDA201901
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer Metastatic
-
Advaxis, Inc.TerminatedMetastatic Melanoma | Urothelial Carcinoma | Metastatic Non-Small Cell Lung Cancer | Head and Neck Cancer Metastatic | Colon Cancer MetastaticUnited States
-
Gottfried MayaUnknownMetastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Gastric Cancer | Metastatic Bladder CancerIsrael
-
Cota Inc.Blue Cross Blue Shield; NantHealth Inc.TerminatedPancreatic Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Melanoma | Metastatic Prostate Cancer | Metastatic Colon CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
Williams Cancer FoundationSyncromune, Inc.RecruitingCancer | Solid Tumor | Metastatic Cancer | Metastatic Lung Cancer | Metastatic Breast CancerMexico
-
Asana BioSciencesCompletedCancer | Neoplasm Metastasis | Pancreatic Cancer | Metastatic Cancer | Metastatic Lung Cancer | Pancreas Adenocarcinoma | Metastatic Melanoma | Colon Cancer | Colonic Neoplasms | Pancreas Cancer | Non Small Cell Lung Cancer Metastatic | Neoplasm | Pancreas Neoplasm | Metastatic Pancreatic Cancer | Metastatic Colon Cancer and other conditionsUnited States
-
Institut Investigacio Sanitaria Pere VirgiliInstitut Català d'Oncologia; Hospital Universitario Ramon y Cajal; Hospital Arnau... and other collaboratorsRecruitingMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastasis | Metastatic Prostate CancerSpain
-
Genentech, Inc.CompletedNon-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, MelanomaUnited States
-
Yale UniversityNational Cancer Institute (NCI)TerminatedCancer Head Neck | Metastatic Cancer | Metastatic Lung CancerUnited States
Clinical Trials on 99mTc-3PRGD2
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityPeking UniversityUnknownEsophageal Cancer | Diagnoses Disease | Lymph Node MetastasesChina
-
First Affiliated Hospital of Fujian Medical UniversityCompleted
-
First Affiliated Hospital of Fujian Medical UniversityCompleted
-
First Affiliated Hospital of Fujian Medical UniversityCompleted
-
Peking Union Medical College HospitalUnknown
-
The First Affiliated Hospital of Xiamen UniversityRecruitingRefractory Solid TumorChina
-
Peking Union Medical College HospitalRecruiting
-
RDO Pharm.Beijing Pharbers Genesis Pharmaceutical Technology Co., Ltd.; MedAlly Solutions...Completed
-
Peking Union Medical College HospitalCompletedBreast CancerChina
-
Molecular Insight Pharmaceuticals, Inc.CompletedProstate CancerUnited States